Short answer
SOLENO THERAPEUTICS INC (SLNO) filed an 8-K current report with the SEC on April 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Neurocrine Biosciences offer: $53.00 cash per Soleno share, followed by acquisition through merger.
SOLENO THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Neurocrine Biosciences offer: $53.00 cash per Soleno share, followed by acquisition through merger
- Tender offer requires more than 50% of outstanding shares; no financing condition
- Offer expected within 10 business days and remains open 20 business days, subject to extensions
- Merger deadline: October 5, 2026; regulatory approval and customary closing conditions apply
- $95.25M Soleno termination fee versus $141.5M Neurocrine antitrust termination fee; insiders support 1.01% of shares
Item 7.01 · Regulation FD Disclosure
- Proposed Neurocrine acquisition remains pending; tender offer has not commenced
- Key next filings: Neurocrine Schedule TO and Soleno Schedule 14D-9
- Transaction completion depends on tender participation, closing conditions, regulatory approvals, and potential competing offers
- Investors face deal-break risk from termination, litigation, funding constraints, and integration challenges
- Soleno’s VYKAT XR commercial uptake and Neurocrine’s financing capacity remain important transaction risks
Item EX-99.1 · Exhibit EX-99.1
- Neurocrine agreed to acquire Soleno for $53.00 per share in cash, valuing Soleno’s equity at $2.9 billion
- Offer represents premiums of 34% to April 2 closing price and 51% to Soleno’s 30-day VWAP
- VYKAT XR generated $190 million in 2025 revenue, including $92 million in fourth-quarter revenue
- Acquisition adds Neurocrine’s third marketed first-in-class medicine alongside INGREZZA and CRENESSITY
- Closing targeted within 90 days, subject to majority tender, Hart-Scott-Rodino clearance, and customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SOLENO THERAPEUTICS INC 8-K filings
Get the next SLNO 8-K as it lands
Follow SLNO for push alerts, or ask the research agent what this filing means.